Gunnar Birgegård

The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

Wondergem, Marielle J.; Almeida, Antonio; Brolin, Janaki; Fernandez de Larrea, Carlos et al.

Part of HemaSphere, 2022

• DOI for The Progress Test of the European Hematology Association: A New Tool for Continuous Learning
• Download full text (pdf) of The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Alvarez-Larran, Alberto; Sant'Antonio, Emanuela; Harrison, Claire; Kiladjian, Jean-Jacques et al.

Part of The Lancet Haematology, 2021

• DOI for Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling

Hjelmgren, Jonas; Nilsson, Kristoffer; Birgegård, Gunnar

Part of Journal of health economics and outcomes research, p. 61-70, 2020

• DOI for JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling
• Download full text (pdf) of JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling

The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Navarro, Jose-Tomas; Birgegård, Gunnar; Strivens, Janet; Hollegien, Wietske W. G. et al.

Part of HemaSphere, 2019

• DOI for The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe
• Download full text (pdf) of The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Birgegård, Gunnar; Samuelsson, Jan; Ahlstrand, Erik; Ejerblad, Elisabeth et al.

Part of European Journal of Haematology, p. 235-240, 2019

• DOI for Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

Wondergem, Marielle J.; Almeida, Antonio; Brolin, Janaki; Fernandez de Larrea, Carlos et al.

Part of HemaSphere, 2022

• DOI for The Progress Test of the European Hematology Association: A New Tool for Continuous Learning
• Download full text (pdf) of The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling

Hjelmgren, Jonas; Nilsson, Kristoffer; Birgegård, Gunnar

Part of Journal of health economics and outcomes research, p. 61-70, 2020

• DOI for JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling
• Download full text (pdf) of JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling

The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Navarro, Jose-Tomas; Birgegård, Gunnar; Strivens, Janet; Hollegien, Wietske W. G. et al.

Part of HemaSphere, 2019

• DOI for The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe
• Download full text (pdf) of The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Birgegård, Gunnar; Samuelsson, Jan; Ahlstrand, Erik; Ejerblad, Elisabeth et al.

Part of European Journal of Haematology, p. 235-240, 2019

• DOI for Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

Birgegård, Gunnar; Folkvaljon, Folke; Garmo, Hans; Holmberg, Lars et al.

Part of Leukemia Research, p. 105-109, 2018

• DOI for Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

Birgegård, Gunnar; Besses, Carlos; Griesshammer, Martin; Gugliotta, Luigi et al.

Part of Haematologica, p. 51-60, 2018

• DOI for Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
• Download full text (pdf) of Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY

Birgegård, Gunnar; Folkvaljon, Yasin; Garmo, Hans; Holmberg, Lars et al.

Part of Haematologica, p. 282-282, 2017

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

Scotch, Allison H; Kosiorek, Heidi; Scherber, Robyn; Dueck, Amylou C et al.

Part of Leukemia Research, p. 34-40, 2017

• DOI for Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Geyer, Holly L.; Kosiorek, Heidi; Dueck, Amylou C.; Scherber, Robyn et al.

Part of Haematologica, p. 85-93, 2017

• DOI for Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
• Download full text (pdf) of Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Which patients with myelofibrosis should receive ruxolitinib therapy?: ELN-SIE evidence-based recommendations

Marchetti, M.; Barosi, G.; Cervantes, F.; Birgegård, Gunnar et al.

Part of Leukemia, p. 882-888, 2017

• DOI for Which patients with myelofibrosis should receive ruxolitinib therapy?: ELN-SIE evidence-based recommendations

Treatment of high risk ET: data from the EXELS study

Birgegård, Gunnar; Besses, C.; Griesshammer, M.; Gugliotta, L. et al.

Part of Leukemia Research, 2016

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial

Birgegård, Gunnar; Henry, David; Glaspy, John; Chopra, Rakesh et al.

Part of Pharmacotherapy, p. 402-414, 2016

• DOI for A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
• Download full text (pdf) of A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease

Geyer, Holly; Scherber, Robyn; Kosiorek, Heidi; Dueck, Amylou C et al.

Part of Journal of Clinical Oncology, p. 151-+, 2016

• DOI for Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease

Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia: Results From The Prospective Long-Term Observational Exels Study

Gugliotta, L.; Tortorella, G.; Besses, C.; Griesshammer, M. et al.

Part of Haematologica, p. 557-557, 2016

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

Geyer, Holly L.; Andreasson, Bjorn; Kosiorek, Heidi E.; Dueck, Amylou C. et al.

Part of Cancer, p. 1888-1896, 2016

• DOI for The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

Development Of An Mf Patient Reported Outcome (Pro) Tool For Fda Qualification: Comprehensive Literature Search And Physician Cognitive Debriefing Results

Geyer, H.; Kosiorek, H.; Dueck, A.; Slot, S. et al.

Part of Haematologica, p. 564-564, 2016

SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT

Scherber, R.; Dueck, A.; Geyer, H.; Kosiorek, H. et al.

Part of Haematologica, p. 557-558, 2016

Rate Of Malignant Transformation In High Risk Et During 5 Years Of Follow-Up Of Cytoreductive Therapy

Birgegård, Gunnar; Folkvaljon, Y.; Garmo, H.; Besses, C. et al.

Part of Haematologica, p. 96-96, 2016

Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features: An Analysis By The Mpn Quality Of Life International Study Group

Geyer, H.; Scherber, R.; Kosiorek, H.; Dueck, A. et al.

Part of Haematologica, p. 555-555, 2016

Advances and challenges in the management of essential thrombocythemia

Birgegård, Gunnar

Part of Therapeutic advances in hematology, p. 142-156, 2015

• DOI for Advances and challenges in the management of essential thrombocythemia

Treatment of essential thrombocythaemia in Europe: an observational study of 3649 high-risk patients in EXELS

Griesshammer, M.; Stegelmann, F.; Mohr, A.; Matzdorff, A. et al.

Part of Oncology Research and Treatment, p. 216-216, 2015

Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation: A pilot study

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

Part of European Journal of Oncology Nursing, p. 50-53, 2015

• DOI for Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation: A pilot study

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

Barosi, G; Tefferi, A; Besses, C; Birgegård, Gunnar et al.

Part of Leukemia, p. 20-26, 2015

• DOI for Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

Treatment of essential thrombocythaemia in Europe: an observational study of 3649 high-risk patients in EXELS

Harrison, C.; Tiplady, C.; Fernandes, S.; Knechtli, C. et al.

Part of British Journal of Haematology, p. 7-7, 2015

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

Dignass, Axel U; Gasche, Christoph; Bettenworth, Dominik; Birgegård, Gunnar et al.

Part of Journal of Crohn's & Colitis, p. 211-222, 2015

• DOI for European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting

Svanberg, Anncarin; Birgegård, Gunnar

Part of Oncology, p. 31-36, 2015

• DOI for Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting

Development of a Progress Test Based on the EHA Curriculum and EHA CV Passport, Used for Yearly Evaluation of Hematology Residency In Sweden

Ungerstedt, J.; Eriksson, Anna; Olander, E.; Bergfelt, Emma et al.

Part of Haematologica, p. 776-776, 2015

PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)

Geyer, H.; Kosiorek, H.; Scherber, R.; Dueck, A. et al.

Part of Haematologica, p. 261-262, 2015

RISK FACTORS FOR THROMBOHEMORRHAGIC AND TRANSFORMATION EVENTS IN 3649 HIGH-RISK PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: RESULTS FROM THE PROSPECTIVE LONG-TERM OBSERVATIONAL EXELS STUDY

Birgegård, Gunnar; Besses, C.; Griesshammer, M.; Gugliotta, L. et al.

Part of Haematologica, p. 160-161, 2015

Treatment Of Essential Thrombocythaemia In Europe: An Observational Study Of 3649 High-Risk Patients In Exels

Gugliotta, L.; Specchia, G.; Gaidano, G.; Scalzulli, P. R. et al.

Part of Haematologica, p. 43-43, 2015

Treatment Of Essential Thrombocythemia In Europe: Observational Study Of 3649 Patients Of High Risk (Exels)

Besses, C.; Bello-Lopez, J. L.; De la Serna, J.; Hernandez-Boluda, J. C. et al.

Part of Haematologica, p. 29-29, 2015

Gender Differences and MPN Symptom Burden: An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG)

Geyer, H.; Emanuel, R.; Dueck, A.; Kiladjian, J. J. et al.

Part of Haematologica, p. 396-397, 2014

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Geyer, Holly L.; Scherber, Robyn M.; Dueck, Amylou C.; Kiladjian, Jean-Jacques et al.

Part of Blood, p. 3803-3810, 2014

• DOI for Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Does anything work for anaemia in myelofibrosis?

Birgegard, Gunnar

Part of Baillière's Best Practice & Research, p. 175-185, 2014

• DOI for Does anything work for anaemia in myelofibrosis?

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid (R) efficacy and long-term safety study

Gugliotta, Luigi; Besses, Carlos; Griesshammer, Martin; Harrison, Claire et al.

Part of Haematologica, p. 679-687, 2014

• DOI for Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid (R) efficacy and long-term safety study

Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy

Hedenus, Michael; Karlsson, Torbjörn; Ludwig, Heinz; Rzychon, Beate et al.

Part of Medical Oncology, p. 302, 2014

• DOI for Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
• Download full text (pdf) of Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy

Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients

Geyer, Holly Lynn; Scherber, Robyn M.; Dueck, Amylou Constance; Kiladjian, Jean-Jacques et al.

Part of Blood, 2014

Treatment of Essential Thrombocythemia in Europe: An Observational Study of 3649 High-Risk Patients in Exels

Birgegård, Gunnar; Besses, Carlos; Griesshammer, Martin; Gugliotta, Luigi et al.

Part of Blood, 2014

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

Besses, Carlos; Kiladjian, Jean-Jacques; Griesshammer, Martin; Gugliotta, Luigi et al.

Part of Leukemia Research, p. 162-168, 2013

• DOI for Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Ejerblad, Elisabeth; Kvasnicka, Hans M; Thiele, Jürgen; Andreasson, Björn et al.

Part of Hematology, p. 8-13, 2013

• DOI for Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged > 80 Years: An Interim Analysis of the EXELS Study

Kiladjian, Jean-Jacques; Besses, Carlos; Griesshammer, Martin; Gugliotta, Luigi et al.

Part of Clinical drug investigation, p. 55-63, 2013

• DOI for Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged > 80 Years: An Interim Analysis of the EXELS Study

Addition of aprepitant (Emend (R)) to standard antiemetic care for seven days post-chemotherapy before stem cell transplantation gives significant reduction of vomiting

Svanberg, Anncarin; Birgegård, Gunnar

Part of Bone Marrow Transplantation, 2013

Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis

Lönnberg, Maria; Garle, Mats; Lönnberg, Lina; Birgegård, Gunnar

Part of Journal of Pharmaceutical and Biomedical Analysis, p. 187-192, 2013

• DOI for Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis
• Download full text (pdf) of Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis

Cytoreductive treatment patterns for essential thrombocythaemia in Europe: analysis of 3643 patients in the EXELS study

Harrison, C.; Besses, C.; Kiladjian, J. J.; Griesshammer, M. et al.

Part of British Journal of Haematology, p. 17-17, 2013

The exels study: Real-world cytoreductive treatment patterns for essential thrombocythaemia in Europe (analysis of 3643 patients)

Griesshammer, M.; Gugliotta, L.; Harrison, C.; Besses, C. R. et al.

Part of Onkologie (Basel), p. 111-111, 2013

Rapid detection of erythropoiesis-stimulating agents in urine and serum

Lönnberg, Maria; Andrén, Maria; Birgegård, Gunnar; Drevin, Malin et al.

Part of Analytical Biochemistry, p. 101-114, 2012

• DOI for Rapid detection of erythropoiesis-stimulating agents in urine and serum

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Abelsson, J; Merup, M; Birgegård, Gunnar; WeisBjerrum, O et al.

Part of Bone Marrow Transplantation, p. 380-386, 2012

• DOI for The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

Johansson, Peter; Mesa, Ruben; Scherber, Robyn; Abelsson, Johanna et al.

Part of Leukemia and Lymphoma, p. 441-444, 2012

• DOI for Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

The effect of cryotherapy on oral mucosa: a study in healthy volunteers

Svanberg, Anncarin; Öhrn, Kerstin; Broström, Hans; Birgegård, Gunnar

Part of Medical Oncology, p. 3587-3591, 2012

• DOI for The effect of cryotherapy on oral mucosa: a study in healthy volunteers

Five year follow-up of survival and relapse in patients who received cryotherapy during high dose chemotherapy for stem cell transplantation shows no safety concerns

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

Part of European Journal of Cancer Care, p. 822-828, 2012

• DOI for Five year follow-up of survival and relapse in patients who received cryotherapy during high dose chemotherapy for stem cell transplantation shows no safety concerns

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Emanuel, Robyn M; Dueck, Amylou C; Geyer, Holly L; Kiladjian, Jean-Jacques et al.

Part of Journal of Clinical Oncology, p. 4098-4103, 2012

• DOI for Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients

Emanuel, Robyn M.; Dueck, Amylou C.; Geyer, Holly Lynn; Kiladjian, Jean-Jacques et al.

Part of Blood, p. 1726, 2012

The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients

Geyer, Holly Lynn; Dueck, Amylou C.; Emanuel, Robyn M.; Kiladjian, Jean-Jacques et al.

Part of Blood, p. 1731, 2012

Combination of Cytoreductive Therapies in Patients with Essential Thrombocythemia: A Preliminary Report From the EXELS Study

Gugliotta, Luigi; Besses, Carlos; Griesshammer, Martin; Harrison, Claire N. et al.

Part of Blood, p. 2842, 2012

Webbaserad pedagogisk meritportfölj: från idé till verklighet

Johansson, Jakob; Apelgren, Karin; Birgegård, Gunnar; Grydén, Martin et al.

Part of Högre Utbildning, p. 27-37, 2011

Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

Aapro, Matti; Beguin, Yves; Birgegård, Gunnar; Gascon, Pere et al.

Part of Journal of Clinical Oncology, 2011

• DOI for Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions

Nilsson-Ehle, Herman; Birgegård, Gunnar; Samuelsson, Jan; Antunovic, Petar et al.

Part of European Journal of Haematology, p. 244-252, 2011

• DOI for Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Scherber, Robyn; Dueck, Amylou C.; Johansson, Peter; Barbui, Tiziano et al.

Part of Blood, p. 401-408, 2011

• DOI for The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Barbui, Tiziano; Barosi, Giovanni; Birgegård, Gunnar; Cervantes, Francisco et al.

Part of Journal of Clinical Oncology, p. 761-770, 2011

• DOI for Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

Björkholm, Magnus; Derolf, Asa R; Hultcrantz, Malin; Kristinsson, Sigurdur Y et al.

Part of Journal of Clinical Oncology, p. 2410-2415, 2011

• DOI for Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

Tobiasson, Magnus; Alyass, Bassam; Söderlund, Susanne; Birgegård, Gunnar

Part of Medical Oncology, p. 105-107, 2010

• DOI for High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

Barosi, Giovanni; Birgegård, Gunnar; Finazzi, Guido; Griesshammer, Martin et al.

Part of British Journal of Haematology, p. 961-963, 2010

• DOI for A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron

Birgegård, Gunnar; Schneider, Karin; Ulfberg, J.

Part of Vox Sanguinis, p. 354-361, 2010

• DOI for High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron

Oral cryotherapy reduces mucositis and improves nutrition: a randomised controlled trial

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

Part of Journal of Clinical Nursing, p. 2146-2151, 2010

• DOI for Oral cryotherapy reduces mucositis and improves nutrition: a randomised controlled trial

Reassessments of ESAs for cancer treatment in the US and Europe

Bennett, Charles L.; McKoy, June M.; Henke, Michael; Silver, Samuel M. et al.

Part of Oncology, p. 260-268, 2010

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Barosi, Giovanni; Birgegård, Gunnar; Finazzi, Guido; Griesshammer, Martin et al.

Part of Blood, p. 4829-4833, 2009

• DOI for Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Medical interns' view of their undergraduate medical education in Uppsala: an alumnus study with clear attitude differences between women and men

Hoppe, Astrid; Persson, Elisabeth; Birgegård, Gunnar

Part of Medical teacher, p. 426-432, 2009

• DOI for Medical interns' view of their undergraduate medical education in Uppsala: an alumnus study with clear attitude differences between women and men

New perspectives in managing myeloproliferative disorders: focus on the patient

Birgegård, Gunnar

Part of Hematological Oncology, p. 5-7, 2009

• DOI for New perspectives in managing myeloproliferative disorders: focus on the patient

Bone marrow fibrosis and diagnosis of essential thrombocythemia

Thiele, Juergen; Kvasnicka, Hans Michael; Vardiman, James W.; Orazi, Attilio et al.

Part of Journal of Clinical Oncology, 2009

• DOI for Bone marrow fibrosis and diagnosis of essential thrombocythemia

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Palmblad, Jan; Björkholm, Magnus; Kutti, Jack; Lärfars, Gerd et al.

Part of International Journal of Medical Sciences, p. 87-91, 2008

Managing anemia in lymphoma and multiple myeloma

Birgegård, Gunnar

Part of Therapeutics and clinical risk management, p. 527-539, 2008

• DOI for Managing anemia in lymphoma and multiple myeloma

Erythropoietins should be used according to guidelines

Aapro, Matti S.; Birgegård, Gunnar; Bokemeyer, Carsten; Cornes, Paul et al.

Part of The Lancet Oncology, p. 412-3, 2008

• DOI for Erythropoietins should be used according to guidelines

Den nya läkarutbildningen i Uppsala: Fallbaserad, integrerad och med tidig patientkontakt

Birgegård, Gunnar; Sandler, Stellan; Bergsten, Johannes; Nilsson, Olle

Part of Läkartidningen, p. 3724-8, 2008

Enkätstudie om AT-läkares syn på sin grundutbildning: Tydliga attitydskillnader mellan kvinnor och män

Hoppe, Astrid; Persson, Elisabeth M.; Birgegård, Gunnar

Part of Läkartidningen, p. 620-3, 2008

Randomized comparison of student-activating and traditional lecture: no learning difference

Birgegård, Gunnar; Persson, Elisabeth; Hoppe, Astrid

Part of Medical teacher, p. 819-819, 2008

• DOI for Randomized comparison of student-activating and traditional lecture: no learning difference

MED NORD - A tool for measuring medical students' well-being and study orientations

Lonka, Kirsti; Sharafi, Parvaneh; Karlgren, Klas; Masiello, Italo et al.

Part of Medical teacher, p. 72-79, 2008

• DOI for MED NORD - A tool for measuring medical students' well-being and study orientations

Patient attitudes, behaviours, and other factors considered by doctors when estimating cancer patients' anxiety and desire for information

Fröjd, Camilla; Lampic, Claudia; Larsson, Gunnel; Birgegård, Gunnar et al.

Part of Scandinavian Journal of Caring Sciences, p. 523-529, 2007

• DOI for Patient attitudes, behaviours, and other factors considered by doctors when estimating cancer patients' anxiety and desire for information

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Ahlqvist-Rastad, Jane; Albertsson, Maria; Bergh, Jonas; Birgegård, Gunnar et al.

Part of Medical Oncology, p. 267-272, 2007

• DOI for Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

Birgegård, Gunnar; Dahl, Fredrik; Glimelius, Bengt; Landegren, Ulf

Part of Medical Oncology, p. 318-322, 2007

• DOI for Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Barosi, G.; Besses, C.; Birgegård, Gunnar; Briere, J. et al.

Part of Leukemia, p. 277-280, 2007

• DOI for A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Hedenus, M.; Birgegård, Gunnar; Näsman, P.; Ahlberg, L. et al.

Part of Leukemia, p. 627-632, 2007

• DOI for Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy-a randomized controlled trial

Svanberg, Anncarin; Birgegård, Gunnar; Öhrn, Kerstin

Part of Supportive Care in Cancer, p. 1155-1161, 2007

• DOI for Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy-a randomized controlled trial

Essential thrombocythaemia treatment options: addressing patient-specific needs

Birgegård, Gunnar

Part of European Journal of Haematology, p. 27-31, 2007

• DOI for Essential thrombocythaemia treatment options: addressing patient-specific needs

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Tefferi, Ayalew; Thiele, Juergen; Orazi, Attilio; Kvasnicka, Hans Michael et al.

Part of Blood, p. 1092-1097, 2007

• DOI for Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment

Hultdin, Magnus; Sundström, Gunnel; Wahlin, Anders; Lundström, Berith et al.

Part of Medical Oncology, p. 63-70, 2007

• DOI for Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment

Epoetin treatment in haernatologic malignancy: How to improve response?

Birgegård, Gunnar

Part of European Journal of Cancer Supplements, p. 436-437, 2007

• DOI for Epoetin treatment in haernatologic malignancy: How to improve response?

Uppsalaprofilen i läkarutbildningen. Människokunskap och biologi förenas.

Birgegard, Gunnar; Eriksson, Ulf

Part of Läkartidningen, p. 299-302, 1995

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Alvarez-Larran, Alberto; Sant'Antonio, Emanuela; Harrison, Claire; Kiladjian, Jean-Jacques et al.

Part of The Lancet Haematology, 2021

• DOI for Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Barbuil, Tiziano; Tefferi, Ayalew; Vannucchi, Alessandro M.; Passamonti, Francesco et al.

Part of Leukemia, p. 1057-1069, 2018

• DOI for Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

Birgegård, Gunnar

Part of Current Hematologic Malignancy Reports, p. 348-355, 2016

• DOI for The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
• Download full text (pdf) of The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

Pharmacological management of essential thrombocythemia

Birgegård, Gunnar

Part of Expert Opinion on Pharmacotherapy, p. 1295-1306, 2013

• DOI for Pharmacological management of essential thrombocythemia

Long-term management of thrombocytosis in essential thrombocythaemia

Birgegård, Gunnar

Part of Annals of Hematology, p. 1-10, 2009

• DOI for Long-term management of thrombocytosis in essential thrombocythaemia

The role of iron supplementation during epoietin treatment for cancer-related anemia

Hedenus, Michael; Birgegård, Gunnar

Part of Medical Oncology, p. 105-115, 2009

• DOI for The role of iron supplementation during epoietin treatment for cancer-related anemia

15. Anemi och järn

Birgegård, Gunnar

Part of Blodets sjukdomar, p. 195-213, Studentlitteratur, 2012

Övriga myeloproliferativa Sjukdomar

Birgegård, Gunnar

Part of Internmedicin, p. 410-418, Liber, 2011

Järnbristanemi och sekundär anemi

Birgegård, Gunnar

Part of Internmedicin, p. 365-371, Liber, 2011